Post-approval studies (Phase 4)UnknownNCT04719221
What this trial is testing
Impact of Evolocumab as an Additional Lipid-lowering Therapy to Changes in Lipid Core Burden Index of Non-culprit Vulnerable Plaque in Patients Who Underwent Percutaneous Coronary Intervention for the Acute Coronary Syndrome
Who this might be right for
Clinical TrialAcute Coronary Syndrome
Korea University Anam Hospital 60